The Supreme Court on Monday issued notice to the Centre on a public interest writ petition against licensing of and trials with the unproven human papillomavirus (HPV) vaccines, ostensibly to treat cervical cancer.
The petition, by Kalpana Mehta and other health activists, cited the Drugs Controller-General of India (DCGI), the Indian Council of Medical Research and others as respondents. It said Gardasil and Cervarix were hazardous HPV vaccines marketed in India by MSD Pharmaceuticals Pvt. Ltd. (a subsidiary of Merck) and GlaxoSmithKline Ltd.
Technology Partners: MimirTech
Links:
[1] http://admin.indiaenvironmentportal.org.in/news/cervical-cancer-drug-trials-risky-says-plea
[2] http://admin.indiaenvironmentportal.org.in/category/newspaper/hindu-new-delhi
[3] http://admin.indiaenvironmentportal.org.in/category/thesaurus/cancer
[4] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[5] http://admin.indiaenvironmentportal.org.in/category/thesaurus/vaccination
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/indian-council-medical-research-icmr
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drug-industry
[8] http://admin.indiaenvironmentportal.org.in/category/thesaurus/genetic-engineering
[9] http://admin.indiaenvironmentportal.org.in/category/thesaurus/ministry-health-and-family-welfare
[10] http://admin.indiaenvironmentportal.org.in/category/thesaurus/health-effects
[11] http://admin.indiaenvironmentportal.org.in/category/thesaurus/health
